Skip to main content
. 2021 Mar 11;11:5675. doi: 10.1038/s41598-021-85023-w

Table 1.

Comparison of general characteristics between patients with diabetic kidney disease according to obstructive sleep apnea.

Total Non OSA or mild OSA Moderate OSA Severe OSA p value
N 214 38 65 111
Sex 0.576
  Females, n (%) 49 (22.9) 10 (26.3) 12 (18.5) 27 (24.3)
  Males, n (%) 165 (77.1) 28 (73.7) 53 (81.5) 84 (75.7)
Age (years) 67 ± 10 67 ± 9 65 ± 10 69 ± 9§ 0.011
BMI (kg/m2) 31.6 ± 5.0 28.9 ± 3.8 31.0 ± 4.2 32.9 ± 5.5†‡ < 0.001
FMI (kg/m2) 11.6 ± 5.0 11.8 ± 4.4 10.9 ± 5.1 12.0 ± 5.1 0.439
Neck circumference (cm) 43 ± 4 42 ± 5 42 ± 4 43 ± 4 0.053
Waist–hip ratio 1.02 ± 0.09 1.01 ± 0.09 1.00 ± 0.08 0.03 ± 0.09 0.075
Smoking status 0.185
  Current smoker, n (%) 33 (15.6) 5 (13.2) 15 (23.8) 13 (11.7)
  Former smoker, n (%) 111 (52.4) 21 (55.3) 33 (52.4) 57 (51.4)
  Never smoker, n (%) 68 (32.1) 12 (31.6) 15 (23.8) 41 (36.9)
Packs × year 46 ± 32 36 ± 32 46 ± 35 49 ± 29 0.241
Duration of diabetes (years) 14 (9–21) 14 (7–20) 15 (10–21) 14 (9–21) 0.642
Duration of diabetic kidney disease (years) 3 (1–6) 3 (1–5) 3 (1–5) 2 (1–6) 0.659
Heart rate (/min) 77 ± 12 79 ± 12 78 ± 13 76 ± 12 0.458
SBP (mmHg) 141 ± 19 145 ± 19 141 ± 18 141 ± 20 0.537
DBP (mmHg) 77 ± 12 77 ± 14 76 ± 12 78 ± 12 0.780
Current treatment
  Oral antidiabetic drugs, n (%) 179 (83.6) 33 (86.8) 51 (78.5) 95 (85.6) 0.393
  Insulin, n (%) 136 (63.6) 20 (52.6) 44 (67.7) 72 (64.9) 0.284
  ACEi, n (%) 77 (36.0) 15 (39.5) 26 (40.0) 36 (32.4) 0.532
  ARBs, n (%) 122 (57.0) 23 (60.5) 32 (49.2) 67 (60.4) 0.316
  MRAs, n (%) 18 (8.4) 5 (13.2) 7 (10.8) 6 (5.4) 0.237
Age-adjusted Charlson index 7.1 ± 2.5 7.0 ± 2.2 6.6 ± 2.8 7.3 ± 2.5 0.196
Physical activity level 0.319
  Low, n (%) 29 (18.1) 2 (8.7) 11 (21.6) 16 (18.6)
  Moderate, n (%) 103 (64.4) 15 (65.2) 29 (56.9) 59 (68.6)
  High, n (%) 28 (17.5) 6 (26.1) 11 (21.6) 11 (12.8)

Values are number (percentage), median (interquartile range [IQR]) or mean ± SD, according their characteristics and distribution. Comparisons were performed by chi-squared test, Kruskal–Wallis test or ANOVA with post-hoc comparisons by Bonferroni test: p < 0.001 vs. non-OSA or mild OSA; p < 0.05, §p < 0.01 vs. moderate OSA.

OSA obstructive sleep apnea, BMI body mass index, FMI fat mass index, SBP systolic blood pressure, DBP diastolic blood pressure, ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers, MRA aldosterone receptor antagonists.